a.k.a. Brands Gets Price Targets Cuts By Analysts After Q4 Results

a.k.a. Brands Holding Corp. (NYSE: AKA) reported weaker-than-expected financial results for the fourth quarter.

a.k.a. Brands Holding Corp. (NYSE:AKA) reported weaker-than-expected financial results for the fourth quarter.

a.k.a. Brands reported quarterly revenue of $149.13 million, missing consensus estimates of $161.95 million. The company reported a loss of $0.03 per share, versus analysts’ estimates of earnings of $0.01 per share.

a.k.a. Brands shares dropped 3.6% to close at $1.33 on Thursday and added 4.5% in after-hours trading.

These analysts made changes to their price targets on a.k.a. Brands following the release of results.

  • Telsey Advisory Group slashed the price target on a.k.a. Brands from $4 to $2. Telsey Advisory Group analyst Dana Telsey downgraded the stock from Outperform to Market Perform.
  • Piper Sandler cut the price target on a.k.a. Brands from $3 to $2. Piper Sandler analyst Edward Yruma downgraded the stock from Overweight to Neutral.
  • Credit Suisse lowered the price target on a.k.a. Brands from $3.5 to $3. Credit Suisse analyst Michael Binetti maintained a Neutral rating.

Now Read This: Fear & Greed Index Moves To 'Fear' Zone; US Stocks Settle Sharply Lower

Total
0
Shares
Related Posts
Read More

Harpoon Therapeutics Presented Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma at ASH 2022; Said 77% (10/13) Objective Response Rate Observed Across Highest Doses (12 and 24 mg)

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the 64th American Society of Hemato

HARP